Trial reportFrontiers in medicine2026
Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ashwagandha ( Methods: 1,200 consenting apparently healthy participants (age 18-70 years) with a negative SARS-CoV-2 RNA assay (RT-PCR using oral and nasal swab) were randomized within 7 days of vaccine administration (primary or booster) to receive oral standardized Ashwagandha (500 mg aqueous root extract) or a matching placebo daily. Participants were monitored every 4 weeks till weeks 28 (study completion) which included comprehensive clinical and laboratory assessment, specific viral RNA and IgG antibody assays (including Wuhan and Delta strain neutralization). Statistical analyses were performed using standard methods, with a two-sided Results: Of the 1,200 randomized participants, 122 (10.2%) were assigned to the SDG (Single Dose Group), 503 (41.9%) to the DDG (Double Dose Group), and 575 (47.9%) to the BDG (Booster Dose Group); overall, 1,032 participants (86%) completed the trial. The safety and tolerability profile of Ashwagandha was comparable to placebo. Adverse events were predominantly gut related and mild, and none caused withdrawal. Following first Covishield™ injection, a persistently higher IgG antibody assay was observed in the Ashwagandha arm (not statistically significant). The cumulative incidence rate of breakthrough infections was 3.9% (95% confidence interval 3.0-5.2%) and did not differ by study intervention. The immunogenic effect of Ashwagandha could not be demonstrated, likely due to a persistently high post-vaccination immune response. In addition, approximately 70% of participants were seropositive for nucleocapsid antibodies at baseline, indicating prior SARS-CoV-2 infection. Conclusion: Prolonged use and tolerability of Ashwagandha in post-vaccinated healthy participants was shown safe but adjunct immunogenicity could not be discerned. Further research is required. Clinical Trial Registration: http://www.clinicaltrials.gov/, identifier CTRI/2021/06/034496.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.